Back to News & Events

CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics

Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. This round included investments from existing supporters Third Kind Venture Capital, Empire State Development, and Red Cell Partners, as well as new strategic investor Bristol Myers Squibb, which has been collaborating with Envisagenics on oncology research since 2022.

Read more about Envisagenics Series B award here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5031
                    [post_author] => 3
                    [post_date] => 2026-08-10 12:17:19
                    [post_date_gmt] => 2026-08-10 16:17:19
                    [post_content] => 

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2706 [post_author] => 3 [post_date] => 2017-06-02 14:04:51 [post_date_gmt] => 2017-06-02 14:04:51 [post_content] => Dr. Sasha Levy, Marsha Laufer Endowed Assistant Professor of Physical and Quantitative Biology for the Laufer Center and the Department of Biochemistry & Cell Biology at Stony Brook University, recently had an article published in Nature Communications related to his research supported by the Long Island Bioscience Hub. In the article, Dr. Levy’s group has described a next-generation high-throughput system for studying protein-protein interactions in yeast, without the limitations of previous techniques, by monitoring relative barcode frequencies across time periods. This allows large scale study of protein interaction changes across dynamic environments, and can be used for rapid drug screening assays. Access the article here. [post_title] => LIBH Researcher Published in Nature Communications [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => libh-researcher-published-in-nature-communications [to_ping] => [pinged] => [post_modified] => 2017-06-02 14:04:51 [post_modified_gmt] => 2017-06-02 14:04:51 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2706 [menu_order] => 144 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 1450 [post_author] => 3 [post_date] => 2015-03-12 16:15:37 [post_date_gmt] => 2015-03-12 16:15:37 [post_content] => Symbiotic Health, Inc, a New York City based company and Center for Biotechnology client, was named "Best in Show" at the first of MABA's 1st Pitch Life Science events in 2015, Symbiotic Health has developed a capsule to help kill Clostridium difficile (Cdiff) infection which causes severe, debilitating diarrhea, is the most frequent hospital-acquired infection in the US and an immediate public health threat that requires urgent and immediate action (CDC). The company's pipeline includes a capsule microbiome therapeutic designed to cure Cdiff by restoring a community of protective bacteria. Dr. Gerard Honig, CEO of Symbiotic Health, presented on behalf of the company. Stephen M. Goodman, Co-founder of Mid Atlantic Bio Angels and a partner at Pryor Cashman LLP in New York City, also a panelist at the event said Dr. Honig's pitch and responses to questions demonstrated both mastery of the competitive space and a willingness to address challenges to his analysis calmly and directly. His style, as well as his substance, exemplified the maxim that it's not just the business plan but the management that ultimately brings a company success. Read more about the company and the competition here. [post_title] => Symbiotic Health Wins Best in Show at 1st Pitch Competition [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => symbiotic-health-wins-best-in-show-at-1st-pitch-competition [to_ping] => [pinged] => [post_modified] => 2016-03-02 17:58:26 [post_modified_gmt] => 2016-03-02 17:58:26 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1450 [menu_order] => 211 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3600 [post_author] => 3 [post_date] => 2020-08-07 11:09:52 [post_date_gmt] => 2020-08-07 11:09:52 [post_content] => Seven companies were chosen by the NIH to receive funding for new technologies to boost their testing capacities and help them ramp up production of millions of coronavirus rapid tests to be made available by September 2020. A total of $248.7 million will be invested and shared by Mesa Biotech, Quidel, Talis Biomedical, Fluidigm, Ginkgo Bioworks, Helix OpCo and Mammoth Biosciences. Read more. (Via BIO Smart Brief/Reuters) [post_title] => 7 Dx firms to share $249M from NIH for COVID-19 testing [post_excerpt] => Seven companies were chosen by the NIH to receive funding for new technologies to boost their testing capacities. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => 7-dx-firms-to-share-249m-from-nih-for-covid-19-testing [to_ping] => [pinged] => [post_modified] => 2024-12-03 14:59:36 [post_modified_gmt] => 2024-12-03 19:59:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3600 [menu_order] => 57 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5031 [post_author] => 3 [post_date] => 2026-08-10 12:17:19 [post_date_gmt] => 2026-08-10 16:17:19 [post_content] =>

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 284 [max_num_pages] => 95 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

SBU President’s Fast Impact Fund (FIF)

More Information

LIBH Researcher Published in Nature Communications

More Information

Symbiotic Health Wins Best in Show at 1st Pitch Competition

More Information

7 Dx firms to share $249M from NIH for COVID-19 testing

More Information